ERBB2 and non-small cell lung carcinoma: Very recently, the most promising and exciting results came from the final analysis of the multicenter phase II trial, DESTINY-Lung01, which evaluated the efficacy of T-Dxd in refractory NSCLC with HER2 molecular alterations.